Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Other Non-Current Liabilities (2016 - 2024)

Historic Other Non-Current Liabilities for Intellia Therapeutics (NTLA) over the last 6 years, with Q4 2024 value amounting to $130.0 million.

  • Intellia Therapeutics' Other Non-Current Liabilities changed N/A to $130.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $130.0 million, marking a year-over-year change of. This contributed to the annual value of $130.0 million for FY2024, which is N/A changed from last year.
  • Intellia Therapeutics' Other Non-Current Liabilities amounted to $130.0 million in Q4 2024.
  • Intellia Therapeutics' 5-year Other Non-Current Liabilities high stood at $130.0 million for Q4 2024, and its period low was $10.8 million during Q2 2022.